Common Approach to Metabolic-Associated Fatty Liver Disease in Patients With Psoriasis: Consensus-Based Recommendations From a Multidisciplinary Group of Experts

Actas Dermosifiliogr. 2023 May;114(5):392-401. doi: 10.1016/j.ad.2023.01.004. Epub 2023 Jan 30.
[Article in English, Spanish]

Abstract

Recent years have seen concerted efforts to understand the relation between psoriasis and metabolic-associated fatty liver disease (MAFLD). Not only is MALFD diagnosed more often in patients with psoriasis, but its clinical course is also more aggressive. A common approach is therefore needed to enable early detection of liver disease coincident with psoriasis. Especially important is an analysis of risks and benefits of potentially hepatotoxic treatments. This consensus paper presents the recommendations of a group of experts in dermatology and hepatology regarding screening for MALFD as well as criteria for monitoring patients and referring them to hepatologists when liver disease is suspected.

Keywords: EHmet; Esteatosis hepática metabólica; Hepatotoxicidad; Hepatotoxicity; MAFLD; Metabolic-associated fatty liver disease; Psoriasis.

Publication types

  • Practice Guideline

MeSH terms

  • Consensus
  • Gastroenterology*
  • Humans
  • Non-alcoholic Fatty Liver Disease* / complications
  • Non-alcoholic Fatty Liver Disease* / diagnosis
  • Patients
  • Psoriasis* / complications